The comparative in-vitro activity of roxithromycin and other antibiotics against Bordetella pertussis

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue SUPPL. B, 1998, Pages 23-27

  Brett, M ^a   Short, P ^a   Beatson, S ^a  

^a INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; ERYTHROMYCIN; MACROLIDE; RIFAMPICIN; ROXITHROMYCIN; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BORDETELLA PERTUSSIS; CHILDHOOD DISEASE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; HORSE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PERTUSSIS; RESPIRATORY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BORDETELLA PERTUSSIS; ERYTHROMYCIN; MICROBIAL SENSITIVITY TESTS; RIFAMPIN; ROXITHROMYCIN; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0031948333     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.suppl_2.23     Document Type: Article

References (26)

1. Reid, S. & Baker, M. (1993). The epidemiology and control of pertussis in New Zealand. Communicable Disease New Zealand 93, 137-42.
2. Short, P. & Baker, M. (1993). Laboratory surveillance of pertussis. Communicable Disease New Zealand 93, 145-6.
3. Hampl, S. D. & Olson, L. C. (1995). Pertussis in the young infant. Seminars in Respiratory Infections 10, 58-62.
4. de Melker, H. E., Conijn-van Spaendonck, M. A., Rumke, H. C., Sprenger, M. J. & Schellekens, J. F. (1995). Whooping cough in The Netherlands, 1989-1994. Nederlands Tijdschrift Voor Genees-kunde 139, 1280-6.
5. Bass, J. W. (1986). Erythromycin for treatment and prevention of pertussis. Pediatric Infectious Diseases 5, 154-7.
6. de Serres, G., Boulianne, N. & Duval, B. (1995). Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. Pediatric Infectious Diseases Journal 14, 969-75.
7. Hardy, D. J., Hensey, D. M., Beyer, J. M., Vojtko, C., McDonald, E. J. & Fernandes, P. B. (1988). Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrobial Agents and Chemotherapy 32, 1710-9.
8. Markham, A. & Faulds, D. (1994). Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs 48, 297-326.
9. Nilsen, O. G. (1995). Pharmacokinetics of macrolides. Comparison of plasma, tissue and free concentrations with special reference to roxithromycin. Infection 23, Suppl. 1, S5-9.
10. Kafetzis, D. A. & Blanc, F. (1987). Efficacy and safety of roxithromycin in treating paediatric patients. A European Multicentre Study. Journal of Antimicrobial Chemotherapy 20, Suppl. B, 171-7.
11. Bégué, P. & Astruc, J. (1995). The overall safety of oral roxithromycin in paediatric clinical studies. Infection 23, Suppl. 1, S25-7.
12. Kurzynski, T. A., Boehm, D. M., Rott-Petri, J. A., Schell, R. F. & Allison, P. E. (1988). Antimicrobial susceptibilities of Bordetella species isolated in a Multicenter Pertussis Surveillance Project. Antimicrobial Agents and Chemotherapy 32, 137-40.
13. Hoppe, J. & Eichhorn, A. (1989). Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis. European Journal of Clinical Microbiology and Infectious Diseases 8, 653-4.
14. Hoppe, J. E. & Haug, A. (1988). Antimicrobial susceptibility of Bordetella pertussis. (Part 1). Infection 16, 126-30.
15. Preston, N. W. (1970). Technical problems in the laboratory diagnosis and prevention of whooping-cough. Laboratory Practice 19, 482-6.
16. National Committee for Clinical Laboratory Standards. (1993). Methods For Dilution Antimicrobial Susceptibility Tests For Bacteria That Grow Aerobically - Third Edition; Approved Standard M7-A3. NCCLS, Villanova, PA.
17. National Committee for Clinical Laboratory Standards. (1994). Performance Standards For Antimicrobial Susceptibility Testing -Fifth Informational Supplement; Document M 100-S5. NCCLS, Villanova, PA.
18. Olsson-Liljequist, B. & the Subcommittee on Standardization of Methodology, Swedish Reference Group for Antibiotics. (1991). Susceptibility of bacteria to roxithromycin and definition of interpretive criteria based on a Swedish multicentre study. In Proceedings of the 17th International Congress of Chemotherapy, Berlin, 1991. Poster No.771.
19. Bergogne-Bérézin, E. (1987). Tissue distribution of roxithromycin. Journal of Antimicrobial Chemotherapy 20, Suppl. B, 113-20.
20. Rimoldi, R., Mangiarotti, P., De Rose, V., Nonis, A., Bertoletti, R. & Grassi, G. G. (1988). Penetration of roxithromycin into bronchial secretions. British Journal of Clinical Practice 42, Suppl. 55, 74-7.
21. Field, L. H. & Parker, C. D. (1980). Antibiotic susceptibility testing of Bordetella pertussis. American Journal of Clinical Pathology 74, 312-6.
22. Hoppe, J. E. & Muller, J. (1990). In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to six new oral cephalosporins. Antimicrobial Agents and Chemotherapy 34, 1442-3.
23. Jenkinson, D. (1995). Natural course of 500 consecutive cases of whooping cough: a general practice population study. British Medical Journal 310, 299-302.
24. Wirsing von Konig, C. H., Postels-Multani, S., Bock, H. L. & Schmitt, H. J. (1995). Pertussis in adults: frequency of transmission after household exposure. Lancet 346, 1326-9.
25. Steketee, R. W., Wassilak, S. G., Adkins, W. N., Burstyn, D. G., Manclark, C. R., Berg, J. et al. (1988). Evidence for a high attack rate and efficacy of erythromycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled. Journal of Infectious Diseases 157, 434-40.
26. Odenholt-Tornqvist, I., Löwdin, E. & Cars, O. (1995). Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. Antimicrobial Agents and Chemotherapy 39, 221-6.